2. Academic Validation
  3. Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma

Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma

  • J Asthma Allergy. 2023 Jan 20:16:123-134. doi: 10.2147/JAA.S392975.
Richard N van Zyl-Smit 1,  Kenneth R Chapman 2,  Huib A M Kerstjens 3,  Christian Gessner 4,  Hironori Sagara 5,  Ana-Maria Tanase 6,  Motoi Hosoe 6,  Abhijit Pethe 7,  David Lawrence 6,  Hanns-Christian Tillmann 8,  Peter D'Andrea 7
Affiliations

Affiliations

  • 1 Division of Pulmonology and UCT Lung Institute, University of Cape Town, Cape Town, South Africa.
  • 2 Division of Respiratory Medicine, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • 3 Department of Pulmonology, University of Groningen, University Medical Center Groningen, and Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands.
  • 4 Universitätsklinikum Leipzig, Germany POIS Leipzig GbR, Leipzig, Germany.
  • 5 Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, Japan.
  • 6 Novartis Pharma AG, Basel, Switzerland.
  • 7 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • 8 Novartis Institutes for BioMedical Research, Translational Medicine, Basel, Switzerland.
PMID: 36714049 DOI: 10.2147/JAA.S392975
Abstract

Background: Once-daily, single-inhaler mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY, an ICS/LABA/LAMA) and MF/IND (an ICS/LABA) via Breezhaler® have been approved for the maintenance treatment of patients with asthma inadequately controlled with medium-or high-dose ICS or medium-or high-dose ICS/LABA treatment.

Objective: Once-daily (o.d.) formulations of MF/IND/GLY and MF/IND at different MF dose strengths have been compared with twice-daily (b.i.d.) fluticasone propionate/salmeterol xinafoate (FLU/SAL), and b.i.d. FLU/SAL+ o.d. tiotropium (TIO) in the PALLADIUM, IRIDIUM and ARGON studies.

Methods: The similarity in study design and consistent outcomes in these studies prompted the pooling of data in this review to better characterise these novel once-daily controller formulations.

Results: Pooled data from PALLADIUM and IRIDIUM studies showed comparable or greater efficacy with o.d. MF/IND formulations versus b.i.d. FLU/SAL. The o.d. MF/IND/GLY was superior to b.i.d. FLU/SAL in the IRIDIUM study, and similar to, if not more efficacious than b.i.d. FLU/SAL + o.d. TIO in the ARGON study.

Conclusion: These formulations therefore provide novel once-daily treatment options for patients across asthma severity and flexibility for clinicians to step-up or step-down the treatment using the same device and formulations.

Keywords

asthma control; bronchodilator; exacerbation; fluticasone/salmeterol; lung function; mometasone/indacaterol; mometasone/indacaterol/glycopyrronium; tiotropium.

Figures
Products